Overview
Various imaging techniques help doctors visualize mesothelioma tumors, assess their size and location, and determine if the cancer has spread. Imaging is typically the first step in the diagnostic process after symptoms appear.
Why This Matters
Imaging provides essential information for staging mesothelioma, planning surgery, and monitoring treatment response. Different imaging modalities offer complementary information about the disease.
Procedures and Tests
Chest X-Ray
Often the first imaging test, can reveal pleural thickening, fluid buildup, or masses. Limited detail for staging.
Usually first imaging testCT Scan (Computed Tomography)
Provides detailed cross-sectional images showing tumor location, size, and spread to nearby structures.
Primary imaging for stagingPET Scan
Uses radioactive glucose to highlight cancer cells, which consume more glucose than normal cells.
Helps detect spread to other areasPET-CT Scan
Combines PET and CT for detailed anatomic and metabolic information in one exam.
Gold standard for stagingMRI
Provides excellent soft tissue detail, especially useful for evaluating chest wall or diaphragm invasion.
Used for surgical planningWhat to Expect
- Most scans are painless and non-invasive
- CT and PET scans may require contrast injection
- Scan duration typically 15-60 minutes
- May need to fast before some exams
- Results usually reviewed within 1-3 days
Advantages
- Non-invasive visualization of tumors
- Essential for accurate staging
- Guides biopsy and treatment planning
- Monitors treatment response over time
Limitations
- Cannot confirm diagnosis without biopsy
- Small tumors may be difficult to detect
- Some scans involve radiation exposure
- May not distinguish cancer from scar tissue
Next Steps After Diagnosis
Once mesothelioma is confirmed, your medical team will work to determine the stage of the disease and develop a treatment plan. This typically involves:
- Additional imaging to assess cancer spread
- Consultation with mesothelioma specialists
- Discussion of treatment options based on cell type and stage
- Consideration of clinical trial eligibility